Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas

14 Nov 2022

Abstract excerpt

PURPOSE: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of patients with clear-cell renal cell carcinomas (ccRCC). Although analyses of transcriptome, genetic alterations, and the tumor microenvironment (TME) have shed light into mechanisms of response and resistance to these agents, the role of epigenetic alterations in this process remains fully unknown. EXPERIMENTAL DESIGN: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Ferroptosis and cancer prognosis
Share to Renal cell carcinoma treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36374555
DOI: 10.1158/1078-0432.ccr-22-2133

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell CarcinomasPMID 36374555Read ↗

An enhancer demethylator phenotype tightly associated with immune exhaustion and resistance to immune checkpoint inhibitors in clear-cell renal cell carcinomasSemantic proximity Read ↗

Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomasSemantic proximity Read ↗

Retroelement Hypomethylation Links Hypoxia Signaling, Immune Phenotypes, and Survival in Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

DNA hypomethylation promotes transposable element expression and activation of immune signaling in renal cell cancerSemantic proximity Read ↗

TERT promoter methylation predicts overall survival, immune cell infiltration and response to immunotherapy in clear cell renal cell carcinomaSemantic proximity Read ↗

Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinomaSemantic proximity Read ↗

The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic TreatmentsSemantic proximity Read ↗

Exploring Chromatin Regulatory Factor Genes as Novel Biomarkers and Immunotherapy Targets through Multi-Omics Analysis in Kidney Renal Clear Cell Carcinoma to Uncover Tumor HeterogeneitySemantic proximity Read ↗

Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinomaSemantic proximity Read ↗

Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinomaSemantic proximity Read ↗

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.Semantic proximity Read ↗

Genomic Profiling and Molecular Characterization of Clear Cell Renal Cell Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.